November 10, 2015

Predicting the Overuse of PCSK-9 Inhibitors

Author Affiliations
  • 1Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota
  • 2Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota
  • 3Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;314(18):1909-1910. doi:10.1001/jama.2015.13414

In July and August of 2015, the US Food and Drug Administration (FDA) approved alirocumab and evolocumab for patients with familial hypercholesterolemia or with clinical atherosclerotic cardiovascular disease (CVD) who are seeking secondary prevention. These monoclonal antibodies inhibit proprotein convertase subtilisin-kexin type 9 (PCSK-9). In phase 3 randomized clinical trials, PCSK-9 inhibitors reduced levels of low-density lipoprotein cholesterol (LDL-C) by 50% to 70% when added to statins. To date, evidence warranting only low confidence in estimates of efficacy (because of very few events) suggests that the use of these agents may reduce the risk of CVD mortality by 50% (95% CI, −10% to 77%) and all-cause mortality by 55% (95% CI, 14% to 77%).1 Little is known about the long-term safety of these drugs.

First Page Preview View Large
First page PDF preview
First page PDF preview